Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Southern First Bancshares, Inc. (SFST) - free report >>
Stoke Therapeutics, Inc. (STOK) - free report >>
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Southern First Bancshares, Inc. (SFST) - free report >>
Stoke Therapeutics, Inc. (STOK) - free report >>
Image: Bigstock
New Strong Buy Stocks for February 14th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Galecto, Inc. (GLTO - Free Report) : This biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 4.9% over the last 60 days.
Galecto, Inc. Price and Consensus
Galecto, Inc. price-consensus-chart | Galecto, Inc. Quote
Lumen Technologies, Inc. (LUMN - Free Report) : This facilities-based technology and communications company has seen the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the last 60 days.
Lumen Technologies, Inc. Price and Consensus
Lumen Technologies, Inc. price-consensus-chart | Lumen Technologies, Inc. Quote
Morphic Holding, Inc. : This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 3.4% over the last 60 days.
Morphic Holding, Inc. Price and Consensus
Morphic Holding, Inc. price-consensus-chart | Morphic Holding, Inc. Quote
Southern First Bancshares, Inc. (SFST - Free Report) : This bank holding company for Southern First Bank has seen the Zacks Consensus Estimate for its current year earnings increasing 13% over the last 60 days
Southern First Bancshares, Inc. Price and Consensus
Southern First Bancshares, Inc. price-consensus-chart | Southern First Bancshares, Inc. Quote
Stoke Therapeutics, Inc. (STOK - Free Report) : This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 4.4% over the last 60 days.
Stoke Therapeutics, Inc. Price and Consensus
Stoke Therapeutics, Inc. price-consensus-chart | Stoke Therapeutics, Inc. Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.